Drug interactions with bacillus anthracis topoisomerase IV: Biochemical basis for quinolone action and resistance

Biochemistry

Volumn 51, Issue 1, 2012, Pages 370-381

  Aldred, Katie J ^a   McPherson, Sylvia A ^b   Wang, Pengfei ^c   Kerns, Robert J ^d   Graves, David E ^c   Turnbough, Charles L ^b   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BACTERIOLOGY; CATALYST ACTIVITY; DISEASES; DNA; DRUG INTERACTIONS; ENZYME INHIBITION;

BACILLUS ANTHRACIS; BIOWEAPONS; CAUSATIVE AGENTS; DNA CLEAVAGE; KETO ACIDS; MUTANT ENZYMES; QUINOLONES; TERNARY COMPLEX; TOPOISOMERASE IV; WILD TYPES;

AMINO ACIDS;

8 METHYLQUINAZOLINE 2,4 DIONE; CIPROFLOXACIN; CP 115953; DNA TOPOISOMERASE IV; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL MUTATION; CONTROLLED STUDY; DNA CLEAVAGE; DRUG MECHANISM; DRUG POTENCY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 84863030593     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi2013905     Document Type: Article

References (71)

1. Mock, M., and Fouet, A. (2001) Anthrax. Annu. Rev. Microbiol. 55, 647-671.
2. Bossi, P., Tegnell, A., Baka, A., Van Loock, F., Hendriks, J., Werner, A., Maidhof, H., and Gouvras, G. (2004) Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax. Eurosurveillance 9, 1-7.
3. Danzig, R. (2005) Proliferation of biological weapons into terrorist hands. In The Challenge of Proliferation: A Report from the Aspen Strategy Group (Campbell, K. M., Ed.) pp 65-84, The Aspen Institute, Washington, DC.
4. Schwartz, M. (2009) Dr. Jekyll and Mr. Hyde: A short history of anthrax. Mol. Aspects Med. 30, 347-355.
5. Waterer, G. W., and Robertson, H. (2009) Bioterrorism for the respiratory physician. Respirology 14, 5-11.
6. Hooper, D. C. (1999) Mode of action of fluoroquinolones. Drugs 58 (Suppl. 2), 6-10. (Pubitemid 29500078)
7. Anderson, V. E., and Osheroff, N. (2001) Type II topoisomerases as targets for quinolone antibacterials: Turning Dr. Jekyll into Mr. Hyde. Curr. Pharm. Des. 7, 337-353. (Pubitemid 32409725)
8. Hooper, D. C. (2001) Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin. Infect. Dis. 32 (Suppl. 1), S9-S15. (Pubitemid 32506740)
9. Drlica, K., Malik, M., Kerns, R. J., and Zhao, X. (2008) Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52, 385-392. (Pubitemid 351170804)
10. Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., and Zhao, X. (2009) Quinolones: Action and resistance updated. Curr. Top. Med. Chem. 9, 981-998.
11. Thompson, K. M., Armstrong, R. E., and Thompson, D. (2005) Bayes bugs, and bioterrorists: Lessons learned from the anthrax attacks, Center for Technology and National Security Policy, National Defense University Press, Washington, DC.
12. Levine, C., Hiasa, H., and Marians, K. J. (1998) DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta 1400, 29-43. (Pubitemid 28475094)
13. Champoux, J. J. (2001) DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413. (Pubitemid 32662215)
14. Velez-Cruz, R., and Osheroff, N. (2004) DNA topoisomerases: Type II. In Encyclopedia of Biological Chemistry, pp 806-811, Elsevier Inc., Amsterdam.
15. Aubry, A., Fisher, L. M., Jarlier, V., and Cambau, E. (2006) First functional characterization of a singly expressed bacterial type II topoisomerase: The enzyme from Mycobacterium tuberculosis. Biochem. Biophys. Res. Commun. 348, 158-165. (Pubitemid 44177674)
16. Schoeffler, A. J., and Berger, J. M. (2008) DNA topoisomerases: Harnessing and constraining energy to govern chromosome topology. Q. Rev. Biophys. 41, 41-101.
17. Deweese, J. E., Osheroff, M. A., and Osheroff, N. (2009) DNA topology and topoisomerases: Teaching a "knotty" subject. Biochem. Mol. Biol. Educ. 37, 2-10.
18. Liu, Z., Deibler, R. W., Chan, H. S., and Zechiedrich, L. (2009) The why and how of DNA unlinking. Nucleic Acids Res. 37, 661-671.
19. Tretter, E. M., Lerman, J. C., and Berger, J. M. (2010) A naturally chimeric type IIA topoisomerase in Aquifex aeolicus highlights an evolutionary path for the emergence of functional paralogs. Proc. Natl. Acad. Sci. U.S.A. 107, 22055-22059.
20. Deweese, J. E., and Osheroff, N. (2009) The DNA cleavage reaction of topoisomerase II: Wolf in sheep's clothing. Nucleic Acids Res. 37, 738-749.
21. Brook, I., Elliott, T. B., Pryor, H. I. II, Sautter, T. E., Gnade, B. T., Thakar, J. H., and Knudson, G. B. (2001) In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents 18, 559-562. (Pubitemid 33152750)
22. Price, L. B., Vogler, A., Pearson, T., Busch, J. D., Schupp, J. M., and Keim, P. (2003) In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob. Agents Chemother. 47, 2362-2365. (Pubitemid 36753604)
23. Grohs, P., Podglajen, I., and Gutmann, L. (2004) Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations. Antimicrob. Agents Chemother. 48, 3024-3027. (Pubitemid 38989170)
24. Bast, D. J., Athamna, A., Duncan, C. L., de Azavedo, J. C., Low, D. E., Rahav, G., Farrell, D., and Rubinstein, E. (2004) Type II topoisomerase mutations in Bacillus anthracis associated with highlevel fluoroquinolone resistance. J. Antimicrob. Chemother. 54, 90-94. (Pubitemid 39028973)
25. Laponogov, I., Sohi, M. K., Veselkov, D. A., Pan, X. S., Sawhney, R., Thompson, A. W., McAuley, K. E., Fisher, L. M., and Sanderson, M. R. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol. 16, 667-669.
26. Laponogov, I., Pan, X. S., Veselkov, D. A., McAuley, K. E., Fisher, L. M., and Sanderson, M. R. (2010) Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One 5, e11338.
27. Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., Huang, J., Jones, E., Jones, J., Brown, K. K., Lewis, C. J., May, E. W., Saunders, M. R., Singh, O., Spitzfaden, C. E., Shen, C., Shillings, A., Theobald, A. J., Wohlkonig, A., Pearson, N. D., and Gwynn, M. N. (2010) Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466, 935-940.
28. Wohlkonig, A., Chan, P. F., Fosberry, A. P., Homes, P., Huang, J., Kranz, M., Leydon, V. R., Miles, T. J., Pearson, N. D., Perera, R. L., Shillings, A. J., Gwynn, M. N., and Bax, B. D. (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 17, 1152-1153.
29. Freudenreich, C. H., and Kreuzer, K. N. (1994) Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex. Proc. Natl. Acad. Sci. U.S.A. 91, 11007-11011. (Pubitemid 24349614)
30. Capranico, G., and Binaschi, M. (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta 1400, 185-194. (Pubitemid 28475103)
31. Fortune, J. M., and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Prog. Nucleic Acid Res. Mol. Biol. 64, 221-253.
32. Pommier, Y., and Marchand, C. (2005) Interfacial inhibitors of protein-nucleic acid interactions. Curr. Med. Chem.: Anti-Cancer Agents 5, 421-429. (Pubitemid 40974814)
33. Fournier, B., Zhao, X., Lu, T., Drlica, K., and Hooper, D. C. (2000) Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: Different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob. Agents Chemother. 44, 2160-2165. (Pubitemid 30484442)
34. Drlica, K., and Zhao, X. (1997) DNA Gyrase, Topoisomerase IV, and the 4-Quinolones. Microbiol. Mol. Biol. Rev. 61, 377-392. (Pubitemid 28090230)
35. Huband, M. D., Cohen, M. A., Zurack, M., Hanna, D. L., Skerlos, L. A., Sulavik, M. C., Gibson, G. W., Gage, J. W., Ellsworth, E., Stier, M. A., and Gracheck, S. J. (2007) In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant Gram-positive and fastidious organism groups. Antimicrob. Agents Chemother. 51, 1191-1201. (Pubitemid 46586793)
36. Morgan-Linnell, S. K., Becnel Boyd, L., Steffen, D., and Zechiedrich, L. (2009) Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 53, 235-241.
37. Dong, S., McPherson, S. A., Wang, Y., Li, M., Wang, P., Turnbough, C. L. Jr., and Pritchard, D. G. (2010) Characterization of the enzymes encoded by the anthrose biosynthetic operon of Bacillus anthracis. J. Bacteriol. 192, 5053-5062.
38. Englund, P. T. (1978) The replication of kinetoplast DNA networks in Crithidia fasciculata. Cell 14, 157-168. (Pubitemid 8340443)
39. Zhang, X., Mu, F., Robinson, B., and Wang, P. (2010) Concise route to the key intermediate for divergent synthesis of C7-substituted fluoroquinolone derivatives. Tetrahedron Lett. 51, 600-601.
40. Malik, M., Marks, K. R., Mustaev, A., Zhao, X., Chavda, K., Kerns, R. J., and Drlica, K. (2011) Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 55, 2335-2343.
41. Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIa by blocking DNA cleavage. J. Biol. Chem. 273, 17643-17650. (Pubitemid 28355102)
42. Anderson, V. E., Gootz, T. D., and Osheroff, N. (1998) Topoisomerase IV catalysis and the mechanism of quinolone action. J. Biol. Chem. 273, 17879-17885. (Pubitemid 28355135)
43. Baldwin, E. L., Byl, J. A., and Osheroff, N. (2004) Cobalt enhances DNA cleavage mediated by human topoisomerase IIa in vitro and in cultured cells. Biochemistry 43, 728-735. (Pubitemid 38114060)
44. O'Reilly, E. K., and Kreuzer, K. N. (2002) A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents. Biochemistry 41, 7989-7997. (Pubitemid 34655165)
45. Robinson, M. J., and Osheroff, N. (1991) Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/ religation equilibrium of topoisomerase II. Biochemistry 30, 1807-1813.
46. Gentry, A. C., Pitts, S. L., Jablonsky, M. J., Bailly, C., Graves, D. E., and Osheroff, N. (2011) Interactions between the etoposide derivative F14512 and human type II topoisomerases: Implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry 50, 3240-3249.
47. Osheroff, N., and Zechiedrich, E. L. (1987) Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: Trapping the covalent enzyme-DNA complex in an active form. Biochemistry 26, 4303-4309.
48. Barnard, F. M., and Maxwell, A. (2001) Interaction between DNA gyrase and quinolones: Effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob. Agents Chemother. 45, 1994-2000. (Pubitemid 32591689)
49. Deweese, J. E., Burgin, A. B., and Osheroff, N. (2008) Human topoisomerase IIa uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Res. 36, 4883-4893.
50. Pitts, S. L., Liou, G. F., Mitchenall, L. A., Burgin, A. B., Maxwell, A., Neuman, K. C., and Osheroff, N. (2011) Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV. Nucleic Acids Res. 39, 4808-4817.
51. Munoz, R., and De la Campa, A. G. (1996) ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40, 2252-2257. (Pubitemid 26328025)
52. Pan, X.-S., Ambler, J., Mehtar, S., and Fisher, L. M. (1996) Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40, 2321-2326. (Pubitemid 26328040)
53. Pan, X.-S., and Fisher, L. M. (1997) Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41, 471-474. (Pubitemid 27111050)
54. Pan, X.-S., and Fisher, L. M. (1998) DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42, 2810-2816. (Pubitemid 28501208)
55. Higgins, P. G., Fluit, A. C., and Schmitz, F. J. (2003) Fluoroquinolones: Structure and target sites. Curr. Drug Targets 4, 181-190. (Pubitemid 36553588)
56. Robinson, M. J., Martin, B. A., Gootz, T. D., McGuirk, P. R., Moynihan, M., Sutcliffe, J. A., and Osheroff, N. (1991) Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J. Biol. Chem. 266, 14585-14592. (Pubitemid 21907543)
57. Anderson, V. E., Zaniewski, R. P., Kaczmarek, F. S., Gootz, T. D., and Osheroff, N. (1999) Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV: Changes in drug mechanism across evolutionary boundaries. J. Biol. Chem. 274, 35927-35932. (Pubitemid 129512900)
58. Anderson, V. E., Zaniewski, R. P., Kaczmarek, F. S., Gootz, T. D., and Osheroff, N. (2000) Action of quinolones against Staphylococcus aureus topoisomerase IV: Basis for DNA cleavage enhancement. Biochemistry 39, 2726-2732. (Pubitemid 30148927)
59. Pan, X. S., Gould, K. A., and Fisher, L. M. (2009) Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob. Agents Chemother. 53, 3822-3831.
60. Oppegard, L. M., Streck, K. R., Rosen, J. D., Schwanz, H. A., Drlica, K., Kerns, R. J., and Hiasa, H. (2010) Comparison of in vitro activities of fluoroquinolone-like 2,4-and 1,3-diones. Antimicrob. Agents Chemother. 54, 3011-3014.
61. Tornaletti, S., and Pedrini, A. M. (1988) Studies on the interaction of 4-quinolones with DNA by DNA unwinding experiments. Biochim. Biophys. Acta 949, 279-287. (Pubitemid 18091732)
62. Palu, G., Valisena, S., Ciarrocchi, G., Gatto, B., and Palumbo, M. (1992) Quinolone binding to DNA is mediated by magnesium ions. Proc. Natl. Acad. Sci. U.S.A. 89, 9671-9675.
63. Fan, J. Y., Sun, D., Yu, H., Kerwin, S. M., and Hurley, L. H. (1995) Self-assembly of a quinobenzoxazine-Mg2+ complex on DNA: A new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex. J. Med. Chem. 38, 408-424.
64. Sissi, C., Perdona, E., Domenici, E., Feriani, A., Howells, A. J., Maxwell, A., and Palumbo, M. (2001) Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions. J. Mol. Biol. 311, 195-203. (Pubitemid 32735324)
65. Tran, T. P., Ellsworth, E. L., Sanchez, J. P., Watson, B. M., Stier, M. A., Showalter, H. D., Domagala, J. M., Shapiro, M. A., Joannides, E. T., Gracheck, S. J., Nguyen, D. Q., Bird, P., Yip, J., Sharadendu, A., Ha, C., Ramezani, S., Wu, X., and Singh, R. (2007) Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors. Bioorg. Med. Chem. Lett. 17, 1312-1320. (Pubitemid 46240852)
66. German, N., Malik, M., Rosen, J. D., Drlica, K., and Kerns, R. J. (2008) Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2, 4-diones. Antimicrob. Agents Chemother. 52, 3915-3921.
67. Willmott, C. J., and Maxwell, A. (1993) A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob. Agents Chemother. 37, 126-127. (Pubitemid 23019183)
68. Noble, C. G., and Maxwell, A. (2002) The role of GyrB in the DNA cleavage-religation reaction of DNA gyrase: A proposed two metal-ion mechanism. J. Mol. Biol. 318, 361-371. (Pubitemid 34734831)
69. Deweese, J. E., Burch, A. M., Burgin, A. B., and Osheroff, N. (2009) Use of divalent metal ions in the DNA cleavage reaction of human type II topoisomerases. Biochemistry 48, 1862-1869.
70. Schmidt, B. H., Burgin, A. B., Deweese, J. E., Osheroff, N., and Berger, J. M. (2010) A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature 465, 641-644.
71. Deweese, J. E., and Osheroff, N. (2010) The use of divalent metal ions by type II topoisomerases. Metallomics 2, 450-459.